CTLA4 and sarcoma: Previous analyses of transcriptomic data from antigen specific T cells in a checkpoint responsive murine sarcoma model have defined alterations in metabolic, signaling and T cell effector pathways after treatment with anti-PD1, anti-CTLA-4 or combination therapy [13].